1-10 of 10
Yvette L. Kasamon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Maryam Sarraf Yazdy, Yvette L. Kasamon, Wenjuan Gu, Lisa R. Rodriguez, Susan Jin, Vishal Bhatnagar, Nicholas C. Richardson, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5521–5526.
https://doi.org/10.1158/1078-0432.CCR-24-1729
Published: 16 December 2024
View article titled, FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas
Open the PDF for FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas in another window
Journal Articles

FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million Tegenge, Adnan A. Jaigirdar, Marc R. Theoret, Tejashri Purohit-Sheth, Yvette L. Kasamon
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2309–2316.
https://doi.org/10.1158/1078-0432.CCR-23-2967
Published: 03 June 2024
View article titled, FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma
Open the PDF for FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma in another window
Journal Articles

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Deepti Telaraja, Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, Ping Li, Elyes Dahmane, Yuching Yang, Justin Earp, Manuela Grimstein, Lisa R. Rodriguez, Marc R. Theoret, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 17–22.
https://doi.org/10.1158/1078-0432.CCR-23-1272
Published: 05 January 2024
View article titled, FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Open the PDF for FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma in another window
Journal Articles

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Poornima Sharma, Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc R. Theoret, Tejashri Purohit-Sheth
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4331–4337.
https://doi.org/10.1158/1078-0432.CCR-23-0568
Published: 01 November 2023
View article titled, FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Open the PDF for FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma in another window
Journal Articles

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Andrea C. Baines, Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru, Nicholas C. Richardson, Ashley Lane, Theresa Carioti, Marc R. Theoret, Richard Pazdur, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2748–2752.
https://doi.org/10.1158/1078-0432.CCR-22-3579
Published: 01 August 2023
View article titled, Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective
Open the PDF for Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective in another window
Journal Articles

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome

Yvette L. Kasamon, Haiyan Chen, R. Angelo de Claro, Lei Nie, Jingjing Ye, Gideon M. Blumenthal, Ann T. Farrell, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7275–7280.
https://doi.org/10.1158/1078-0432.CCR-19-2030
Published: 13 December 2019
View article titled, FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome
Open the PDF for FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro, Bindu George, Xue Lin, Shiowjen Lee, Gideon M. Blumenthal, Wilson Bryan, Amy E. McKee, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1702–1708.
https://doi.org/10.1158/1078-0432.CCR-18-2743
Published: 15 March 2019
View article titled, FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Open the PDF for FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma in another window
Journal Articles

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

B. Douglas Smith, Yvette L. Kasamon, Jeanne Kowalski, Christopher Gocke, Kathleen Murphy, Carole B. Miller, Elizabeth Garrett-Mayer, Hua-Ling Tsai, Lu Qin, Christina Chia, Barbara Biedrzycki, Thomas C. Harding, Guang Haun Tu, Richard Jones, Kristen Hege, Hyam I. Levitsky
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 338–347.
https://doi.org/10.1158/1078-0432.CCR-09-2046
Published: 04 January 2010
View article titled, K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
Open the PDF for K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

Yvette L. Kasamon, Ian W. Flinn, Michael R. Grever, Louis F. Diehl, Elizabeth Garrett-Mayer, Steven N. Goodman, Margaret S. Lucas, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (23): 8413–8417.
https://doi.org/10.1158/1078-0432.CCR-05-1612
Published: 01 December 2005
View article titled, Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia
Open the PDF for Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia in another window
Journal Articles

MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma

Tomohide Tatsumi, Lisa S. Kierstead, Elena Ranieri, Loreto Gesualdo, Francesco P. Schena, James H. Finke, Ronald M. Bukowski, Vladimir Brusic, John Sidney, Alessandro Sette, Theodore F. Logan, Yvette L. Kasamon, Craig L. Slingluff, Jr., John M. Kirkwood, Walter J. Storkus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 947–954.
Published: 01 March 2003
View article titled, MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma
Open the PDF for MAGE-6 Encodes HLA-DRβ1*0401-presented Epitopes Recognized by CD4+ T Cells from Patients with Melanoma or Renal Cell Carcinoma in another window